The Europe acute respiratory distress syndrome (ARDS) treatment market is expected to reach USD 2,764,971.40 thousand by 2030, from USD 1,356,879.02 thousand in 2022, growing at the CAGR of 9.7% in the forecast period of 2023 to 2030. Market Segmentation Europe Acute Respiratory Distress Syndrome (Ards) Treatment Market, By Type (Mechanical Ventilation, Corticosteroids, Antiviral Medication, Extracorporeal Membrane Oxygenation (ECMO), Tocilizumab, and Others), Cause ( Sepsis, Inhalation of Harmful Substances, Severe Pneumonia, and Others), Route of Administration (Parenteral, Oral, and Others), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Germany, France, U.K., Italy, Spain, Turkey, Hungary, Netherlands, Switzerland, Austria Lithuania, Poland, Russia, Ireland, Norway, and rest of Europe) - Industry Trends and Forecast to 2030. Overview of Europe Acute Respiratory Distress Syndrome (ARDS) Treatment Market Dynamics Driver • Increasing prevalence and incidence of acute lung injury in the market Restraint • High cost of device and treatment Opportunity • Strategic initiatives joined with new product launches by market players Market Players Some of the major market players operating in the Europe Acute Respiratory Distress Syndrome (ARDS) market are listed below: • Gilead Sciences, Inc. • Terumo Medical Corporation • Getinge AB. • LivaNova PLC • Medtronic • ResMed • Fisher & Paykel Healthcare Limited. • Drägerwerk AG & Co. KGaA • NIPRO • Fresenius SE & Co. KGaA • Hamilton Medical • Pfizer Inc. • WEINMANN Emergency Medical Technology GmbH + Co. KG • EUROSETS • Armstrong Medical • nice Neotech Medical Systems Pvt. Ltd. • Besmed Health Business Corp.

1 INTRODUCTION 22 1.1 OBJECTIVES OF THE STUDY 22 1.2 MARKET DEFINITION 22 1.3 OVERVIEW OF EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET 22 1.4 LIMITATIONS 24 1.5 MARKETS COVERED 24 2 MARKET SEGMENTATION 26 2.1 MARKETS COVERED 26 2.2 GEOGRAPHICAL SCOPE 27 2.3 YEARS CONSIDERED FOR THE STUDY 28 2.4 CURRENCY AND PRICING 28 2.5 DBMR TRIPOD DATA VALIDATION MODEL 29 2.6 MULTIVARIATE MODELLING 32 2.7 TYPE LIFELINE CURVE 32 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 33 2.9 DBMR MARKET POSITION GRID 34 2.10 MARKET END USER COVERAGE GRID 35 2.11 VENDOR SHARE ANALYSIS 36 2.12 SECONDARY SOURCES 37 2.13 ASSUMPTIONS 37 3 EXECUTIVE SUMMARY 38 4 PREMIUM INSIGHTS 41 4.1 PESTEL ANALYSIS 42 4.2 PORTER’S FIVE FORCES 43 4.3 INSURANCE REIMBURSEMENT 44 4.3.1 CENTER FOR MEDICARE SERVICES (CMS)-ELSO (EXTRACORPOREAL LIFE SUPPORT ORGANIZATION) 44 4.3.2 HEALTH RESOURCES AND SERVICES ADMINISTRATION 44 4.3.3 ABBOTT CODING GUIDE FOR ECMO 45 4.3.4 CENTRAL GOVERNMENT HEALTH SCHEME (CGHS) 45 4.3.5 CERN HEALTH INSURANCE SCHEME 46 4.3.6 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - (MEDICARE & MEDICAID) 46 4.3.7 AMERICAN HOSPITAL ASSOCIATION 47 4.4 PIPELINE ANALYSIS 48 4.5 PRICING ANALYSIS 50 5 MARKET OVERVIEW 51 5.1 DRIVERS 53 5.1.1 INCREASING PREVALENCE AND INCIDENCE OF ACUTE LUNG INJURY 53 5.1.2 WIDE RANGE OF RISK FACTORS FOR ARDS TREATMENT 53 5.1.3 RISING RATE OF AIR POLLUTION AND UNHEALTHY LIFESTYLE 54 5.1.4 INCREASING ACCIDENT RATES AND TRAUMA CAUSING ARDS 54 5.2 RESTRAINTS 55 5.2.1 COMPLICATIONS ASSOCIATED WITH THE TREATMENT 55 5.2.2 HIGH COST OF DEVICES AND TREATMENT 55 5.3 OPPORTUNITIES 56 5.3.1 RISING HEALTHCARE EXPENDITURE TO IMPROVE TREATMENT FACILITIES 56 5.3.2 STRATEGIC INITIATIVES JOINED WITH NEW PRODUCT LAUNCH BY MARKET PLAYERS 56 5.3.3 IMPROVING AWARENESS REGARDING ARD SYNDROME 57 5.4 CHALLENGES 58 5.4.1 STRINGENT RULES & REGULATIONS 58 5.4.2 MULTIPLE CHALLENGES FACED BY ICU STAFF 59 6 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY TYPE 60 6.1 OVERVIEW 61 6.2 MECHANICAL VENTILATION 64 6.2.1 HIGH-FLOW NASAL O2 65 6.2.2 BI-LEVEL POSITIVE AIRWAY PRESSURE 65 6.2.3 CONTINUOUS POSITIVE AIRWAY PRESSURE 65 6.2.4 PRONE POSITION VENTILATION 65 6.2.5 OTHERS 66 6.3 CORTICOSTEROIDS 66 6.3.1 METHYLPREDNISOLONE 67 6.3.2 DEXAMETHASONE 67 6.3.3 OTHERS 67 6.4 ANTIVIRAL MEDICATION 68 6.4.1 RIBAVIRIN 69 6.4.2 OSELTAMIVIR 69 6.4.3 OTHERS 69 6.5 EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) 69 6.6 TOCILIZUMAB 70 6.7 OTHERS 70 7 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY CAUSE 71 7.1 OVERVIEW 72 7.2 SEPSIS 75 7.3 INHALATION OF HARMFUL SUBSTANCES 75 7.4 SEVERE PNEUMONIA 76 7.5 OTHERS 76 8 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 77 8.1 OVERVIEW 78 8.2 PARENTERAL 81 8.2.1 INTRAVENOUS 81 8.2.2 INTRAMUSCULAR 81 8.3 ORAL 82 8.4 OTHERS 82 9 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY END USER 83 9.1 OVERVIEW 84 9.2 HOSPITALS 87 9.3 SPECIALTY CLINICS 87 9.4 HOME HEALTHCARE 88 9.5 OTHERS 88 10 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 89 10.1 OVERVIEW 90 10.2 DIRECT TENDER 93 10.3 HOSPITAL PHARMACY 93 10.4 RETAIL PHARMACY 94 10.5 ONLINE PHARMACY 94 11 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, BY REGION 95 11.1 EUROPE 97 11.1.1 GERMANY 102 11.1.2 FRANCE 107 11.1.3 U.K 112 11.1.4 ITALY 117 11.1.5 SPAIN 122 11.1.6 TURKEY 127 11.1.7 NETHERLANDS 132 11.1.8 SWITZERLAND 137 11.1.9 BELGIUM 142 11.1.10 RUSSIA 147 11.1.11 REST OF EUROPE 152 12 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT MARKET, COMPANY LANDSCAPE 153 12.1 COMPANY SHARE ANALYSIS: EUROPE 153 13 SWOT ANALYSIS 154 14 EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) TREATMENT, CPS 155 14.1 GILEAD SCIENCES INC 155 14.1.1 COMPANY SNAPSHOT 155 14.1.2 REVENUE ANALYSIS 156 14.1.3 COMPANY SHARE ANALYSIS 156 14.1.4 PRODUCT PORTFOLIO 157 14.1.5 RECENT DEVELOPMENT 157 14.2 TERUMO CORPORATION 158 14.2.1 COMPANY SNAPSHOT 158 14.2.2 REVENUE ANALYSIS 158 14.2.3 COMPANY SHARE ANALYSIS 159 14.2.4 PRODUCT PORTFOLIO 159 14.2.5 RECENT DEVELOPMENT 159 14.3 GETINGE 160 14.3.1 COMPANY SNAPSHOT 160 14.3.2 REVENUE ANALYSIS 160 14.3.3 COMPANY SHARE ANALYSIS 161 14.3.4 PRODUCT PORTFOLIO 161 14.3.5 RECENT DEVELOPMENT 161 14.4 LIVANOVA PLC 162 14.4.1 COMPANY SNAPSHOT 162 14.4.2 REVENUE ANALYSIS 162 14.4.3 COMPANY SHARE ANALYSIS 163 14.4.4 PRODUCT PORTFOLIO 163 14.4.5 RECENT DEVELOPMENTS 163 14.5 MEDTRONIC 164 14.5.1 COMPANY SNAPSHOT 164 14.5.2 REVENUE ANALYSIS 164 14.5.3 COMPANY SHARE ANALYSIS 165 14.5.4 PRODUCT PORTFOLIO 165 14.5.5 RECENT DEVELOPMENTS 165 14.6 ARMSTRONG MEDICAL 166 14.6.1 COMPANY SNAPSHOT 166 14.6.2 PRODUCT PORTFOLIO 166 14.6.3 RECENT DEVELOPMENT 166 14.7 BESMED HEALTH BUSINESS CORP 167 14.7.1 COMPANY SNAPSHOT 167 14.7.2 PRODUCT PORTFOLIO 167 14.7.3 RECENT DEVELOPMENTS 168 14.8 DRÄGERWERK AG & CO. KGAA 169 14.8.1 COMPANY SNAPSHOT 169 14.8.2 REVENUE ANALYSIS 169 14.8.3 PRODUCT PORTFOLIO 170 14.8.4 RECENT DEVELOPMENTS 170 14.9 EUROSETS 171 14.9.1 COMPANY SNAPSHOT 171 14.9.2 PRODUCT PORTFOLIO 171 14.9.3 RECENT DEVELOPMENT 171 14.10 FISHER & PAYKEL HEALTHCARE LIMITED 172 14.10.1 COMPANY SNAPSHOT 172 14.10.2 REVENUE ANALYSIS 172 14.10.3 PRODUCT PORTFOLIO 173 14.10.4 RECENT DEVELOPMENTS 173 14.11 FRESENIUS SE & CO. KGAA 174 14.11.1 COMPANY SNAPSHOT 174 14.11.2 REVENUE ANALYSIS 174 14.11.3 PRODUCT PORTFOLIO 175 14.11.4 RECENT DEVELOPMENT 175 14.12 HAMILTON MEDICAL 176 14.12.1 COMPANY SNAPSHOT 176 14.12.2 PRODUCT PORTFOLIO 176 14.12.3 RECENT DEVELOPMENT 176 14.13 NICE NEOTECH MEDICAL SYSTEMS PVT.LTD 177 14.13.1 COMPANY SNAPSHOT 177 14.13.2 PRODUCT PORTFOLIO 177 14.13.3 RECENT DEVELOPMENT 177 14.14 NIPRO 178 14.14.1 COMPANY SNAPSHOT 178 14.14.2 REVENUE ANALYSIS 178 14.14.3 PRODUCT PORTFOLIO 179 14.14.4 RECENT DEVELOPMENT 179 14.15 PFIZER INC 180 14.15.1 COMPANY SNAPSHOT 180 14.15.2 REVENUE ANALYSIS 180 14.15.3 PRODUCT PORTFOLIO 181 14.15.4 RECENT DEVELOPMENT 181 14.16 RESMED 182 14.16.1 COMPANY SNAPSHOT 182 14.16.2 REVENUE ANALYSIS 182 14.16.3 PRODUCT PORTFOLIO 183 14.16.4 RECENT DEVELOPMENT 183 14.17 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG 184 14.17.1 COMPANY SNAPSHOT 184 14.17.2 PRODUCT PORTFOLIO 184 14.17.3 RECENT DEVELOPMENT 184 15 QUESTIONNAIRE 185 16 RELATED REPORTS 188